Reinhard Kandera
Director of Finance/CFO bij HOOKIPA PHARMA INC.
Vermogen: 30 682 $ op 31-03-2024
Oorsprong van het eerstegraads netwerk van Reinhard Kandera
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Public Company | Biotechnology | 26 | |
Intercell AG
 Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria.
16
| Extinct | Pharmaceuticals: Major | 16 |
11
| Public Company | Biotechnology | 11 |
| Subsidiary | Biotechnology | 9 | |
Vaccines Holdings Sweden AB
 Vaccines Holdings Sweden AB BiotechnologyHealth Technology Part of Valneva SE, Vaccines Holdings Sweden AB develops and distributes vaccines and biological products. The private company is based in Solna, Sweden. Franck Charles Marie Grimaud has been the CEO of the Swedish company since 2014.
5
| Subsidiary | Biotechnology | 5 |
Elatos GmbH
1
| Subsidiary | 1 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Reinhard Kandera via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| AMGEN INC. | Pharmaceuticals: Major | Director of Finance/CFO Chief Tech/Sci/R&D Officer | |
MedImmune LLC
 MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Sales & Marketing | |
ID Biomedical Corp.
 ID Biomedical Corp. Medical SpecialtiesHealth Technology ID Biomedical Corp. develops gene-based disease testing and subunit vaccines. It conducts research, development, manufacturing, sales, and marketing from its facilities in Canada and in the United States. The company was founded in 1991 and is headquartered in Vancouver, Canada. | Medical Specialties | Director/Board Member Chief Operating Officer | |
| NOVAVAX, INC. | Biotechnology | Chief Tech/Sci/R&D Officer Director/Board Member | |
Seqirus Vaccines Ltd.
 Seqirus Vaccines Ltd. BiotechnologyHealth Technology Seqirus Vaccines Ltd. manufactures vaccines. The company is headquartered in Maidenhead, the United Kingdom. | Biotechnology | Sales & Marketing Director of Finance/CFO | |
Novartis Corp.
 Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Aeras Global TB Vaccine Foundation
 Aeras Global TB Vaccine Foundation Miscellaneous Commercial ServicesCommercial Services Aeras Global TB Vaccine Foundation is a non-profit organization, which engages in the development of tuberculosis vaccines in partnership with other biotech, pharmaceutical, and academic organizations. Its product pipeline includes AdS Ag85A, MTBCAV, VPM 1002, and RUTI. The company is headquartered in Rockville, MD. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Biotechnology | Public Communications Contact Director/Board Member | |
| GSK PLC | Pharmaceuticals: Major | Director of Finance/CFO General Counsel | |
| Dartmouth College | College/University | Undergraduate Degree Undergraduate Degree | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Graduate Degree Undergraduate Degree Graduate Degree | |
| EVOTEC SE | Pharmaceuticals: Major | Chief Executive Officer Chief Executive Officer | |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
Powderject Pharmaceuticals Plc
 Powderject Pharmaceuticals Plc Medical SpecialtiesHealth Technology Powderject Pharmaceuticals Plc develops pharmaceutical products. It offers researching, developing, manufacturing and marketing for existing and next generation vaccines. The company was founded in 1993 and is located in Oxford, UK | Medical Specialties | Director/Board Member Chief Operating Officer Director/Board Member | |
| SOITEC | Electronic Components | Director/Board Member | |
| Karolinska Institutet | College/University | Chairman Chairman | |
| University of California, Berkeley | College/University | Doctorate Degree Undergraduate Degree | |
| University of Maryland | College/University | Undergraduate Degree Doctorate Degree | |
| University of Vienna | College/University | Doctorate Degree Doctorate Degree | |
| INNATE PHARMA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Biovertis AG
 Biovertis AG Pharmaceuticals: MajorHealth Technology Biovertis AG operates as a clinical stage pharmaceutical company. It develops small molecule drugs against proprietary microbial antigens. The firm discovers and develops antimicrobial drugs for infections caused by antibiotic-resistant bacterial pathogens. The company was founded by Erich Felber, Uwe von Ahsen, and Alexander Ullrich von Gabain in 2003 and is headquartered in Vienna, Austria. | Pharmaceuticals: Major | Chairman Chairman Founder | |
| Ruprecht-Karls-Universität Heidelberg | College/University | Doctorate Degree Doctorate Degree | |
| University of Basel | College/University | Corporate Officer/Principal Corporate Officer/Principal | |
| University of Geneva | College/University | Corporate Officer/Principal Corporate Officer/Principal | |
Royal Swedish Academy of Engineering Sciences
 Royal Swedish Academy of Engineering Sciences Miscellaneous Commercial ServicesCommercial Services The Royal Swedish Academy of Engineering Sciences (IVA) is an organization that brings together around 1,300 academy members and 250 companies to bridge the gap between academia, business, and politics. The non-profit company is based in Stockholm, Sweden. The Swedish company's aim is to work towards people's ability to contribute positively to society. The organization runs an internship program called Tekniksprånget, which gives young people in Sweden the opportunity to test the engineering profession through a four-month paid internship. The program has been running since 2012 and aims to inspire more people to choose a higher technical education. The CEO of the company is Björn O. Nilsson. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
Sanofi Pasteur
 Sanofi Pasteur BiotechnologyHealth Technology Sanofi Pasteur SA develops, manufactures and supplies vaccines. It provides vaccines for bacterial and viral diseases, including diphtheria, typhoid fever, and poliomyelitis. The company was founded in 1990 and is headquartered in Lyon, France. | Biotechnology | President General Counsel | |
Crescendo Biologics Ltd.
 Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Valneva Scotland Ltd.
 Valneva Scotland Ltd. BiotechnologyHealth Technology Part of Valneva SE, Valneva Scotland Ltd. is a British vaccine company that specializes in the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The private company is based in Livingston, UK. The company has several vaccines in development, including unique vaccines against Lyme disease, COVID-19, and chikungunya. Valneva's portfolio also includes two commercial vaccines for travelers. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
Hookipa Biotech AG
 Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | Medical Specialties | Director/Board Member Chief Executive Officer Chairman Director/Board Member Director/Board Member Chief Executive Officer Founder Director/Board Member | |
| UNIQURE N.V. | Biotechnology | Chief Executive Officer Founder | |
| Johns Hopkins Bloomberg School of Public Health | College/University | Corporate Officer/Principal Graduate Degree | |
| Smol Therapeutics SAS | Chief Executive Officer Chairman | ||
| Vivalis Toyama Japan KK | Chairman Director/Board Member | ||
Valneva Austria GmbH
 Valneva Austria GmbH Miscellaneous Commercial ServicesCommercial Services Part of Valneva SE, VALNEVA Austria GmbH is an Austrian biotechnology company that develops and commercializes vaccines for infectious diseases. The private company is based in Vienna, Austria. The CEOs are Thomas Lingelbach, Franck Charles Marie Grimaud, Frédéric Jacotot. The company was founded in 2013. | Miscellaneous Commercial Services | Corporate Officer/Principal Chief Executive Officer Chief Executive Officer Chief Executive Officer | |
BliNK Biomedical SAS
 BliNK Biomedical SAS BiotechnologyHealth Technology BliNK Biomedical SAS is a French company that specializes in cutting-edge technology for identifying rare antibody-secreting cells from humans and other species. The company is based in Marseille, France. The company's technology is based on validated platforms, isaac and vivascreen, which provide a highly efficient and deep mining process. The CEO of the company is Jack Elands. | Biotechnology | Director/Board Member Director/Board Member | |
Valneva Sweden AB
 Valneva Sweden AB BiotechnologyHealth Technology Part of Valneva SE, Valneva Sweden AB is a specialty vaccine company that focuses on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The private company is based in Solna, Sweden and is primarily focused on marketing and distributing Valneva's vaccines Dukoral®, Ixiaro®, and Kamrab™. Valneva has several vaccines in development, including unique vaccines against Lyme disease, COVID-19, and Chikungunya. Additionally, Valneva's portfolio includes two commercial vaccines for travelers. | Biotechnology | Director/Board Member Director/Board Member Chairman Director/Board Member | |
| Intercell Austria AG | Corporate Officer/Principal Chief Executive Officer | ||
Valneva UK Ltd.
 Valneva UK Ltd. Medical/Nursing ServicesHealth Services Part of Valneva SE, Valneva UK Ltd. provides health care services. The private company is based in London, UK and was founded in 2015. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
Valneva Canada, Inc.
 Valneva Canada, Inc. Medical DistributorsDistribution Services Part of Valneva SE, Valneva Canada, Inc. engages in marketing and distribution of vaccines. The private company is based in Kirkland, Canada. | Medical Distributors | Director/Board Member President Director/Board Member | |
HotSpot Therapeutics, Inc.
 HotSpot Therapeutics, Inc. BiotechnologyHealth Technology HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA. | Biotechnology | Director/Board Member Corporate Officer/Principal | |
GeneSpire Srl
 GeneSpire Srl BiotechnologyHealth Technology GeneSpire Srl is a holding company, which engages in the development of transformative gene therapies for patients with genetic diseases. The company was founded by Luigi Naldini and Alessio Cantone in March 2020 and is headquartered in Milan, Italy. | Biotechnology | Chairman Director/Board Member | |
| Valneva USA, Inc. | Director/Board Member Chief Executive Officer Chief Executive Officer | ||
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor Private Equity Investor |
Statistieken
Internationaal
| Verenigde Staten | 17 |
| Verenigd Koninkrijk | 7 |
| Frankrijk | 7 |
| Oostenrijk | 6 |
| Duitsland | 4 |
Sectoraal
| Health Technology | 28 |
| Consumer Services | 11 |
| Commercial Services | 6 |
| Electronic Technology | 2 |
| Health Services | 2 |
Operationeel
| Director/Board Member | 315 |
| Corporate Officer/Principal | 129 |
| Chairman | 68 |
| Independent Dir/Board Member | 60 |
| Chief Executive Officer | 41 |
Sterkste connecties
| Insiders | |
|---|---|
| Anne-Sophie Herelle | 65 |
| Hans Lennart Rudolf Wigzell | 30 |
| David Lawrence | 29 |
| Michel Gréco | 28 |
| Graziano Seghezzi | 26 |
| David Ebsworth | 26 |
| James Sulat | 23 |
| Thomas D. Szucs | 23 |
| Franck Grimaud | 22 |
| Michael Kelly | 19 |
| Ernst-Günter Afting | 19 |
| Sander J. van Deventer | 17 |
| Thomas Lingelbach | 17 |
| Christoph S. Lengauer | 16 |
| Mustapha Bakali | 16 |
- Beurs
- Insiders
- Reinhard Kandera
- Bedrijfsconnecties
